Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CGEN vs ACRS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)
CGEN Overall Winner
6-Pillar Tally: CGEN 5 – 1 ACRS
Matrix Metrics: CGEN 9 – 1 ACRS
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas ACRS carries 44.7/100 (HOLD) at $3.38 (N/M Forward P/E, -1412.4% operating margin).
- Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CGEN vs ACRS
CGEN
Head-to-Head Winner
Compugen Ltd
$2.02
-0.98% 1D
Market Cap
$193.2M
TTM Revenue
$76M
Forward P/E
12.4x
Beta / 30D Vol
1.44β · 62% Vol
Unified Composite Score
47.1
HOLD
Tech 44.0
Fund 52.0
Flow 54.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
ACRS
Aclaris Therapeutics, Inc.
$3.38
-6.24% 1D
Market Cap
$548.0M
TTM Revenue
$6.4M
Forward P/E
N/M
Beta / 30D Vol
1.57β · 75% Vol
Unified Composite Score
44.7
HOLD
Tech 41.0
Fund 54.0
Flow 64.0
Mom 70.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CGEN 5 – 1 ACRS)
1. Valuation Multiples
CGEN
Forward P/E
12.4x
N/M
Trailing P/E
5.2x
N/M
PEG Ratio
1.29x
N/M
EV / Revenue
2.5x
85.6x
2. Growth & Scale
CGEN
Revenue Growth (YoY)
+102.1%
-55.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$76M
$6.4M
Market Cap
$193.2M
$548.0M
3. Profitability & Quality
CGEN
Gross Margin
86.2%
N/A
Operating Margin
41.3%
-1412.4%
Net Profit Margin
47.9%
0.0%
Return on Equity (ROE)
57.2%
-55.5%
4. Balance Sheet & Cash Flow
CGEN
Cash Generation (TTM)
$32M EBITDA
-$75M
Cash Flow Margin
41.9% EBITDA Mgn
N/A
Net Cash / Leverage
$4.3M Net Cash
$1.11 Book/Sh · -55.5% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ACRS
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
89.7% (57th %ile)
60.7% (1st %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
CGEN
OpEx & R&D Intensity
44.9% of Rev ($34M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CGEN (9) vs ACRS (1)| Institutional Metric | CGEN | ACRS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $193.2M | $548.0M | ACRS | |
| Trailing P/E Ratio | 5.2x | N/M | CGEN | |
| Forward P/E Ratio | 12.4x | N/M | CGEN | |
| Revenue Growth (YoY) | +102.1% | -55.1% | CGEN | |
| Operating Margin (TTM) | 41.3% | -1412.4% | CGEN | |
| Net Profit Margin | 47.9% | 0.0% | CGEN | |
| Return on Equity (ROE) | 57.2% | -55.5% | CGEN | |
| 52-Week Range Position | 33% ($1–$3) | 26% ($2–$7) | CGEN | |
| Beta / 30D Volatility | 1.44β · 62% Vol | 1.57β · 75% Vol | CGEN | |
| Unified Institutional Score | 47.1 / 100 (HOLD) | 44.7 / 100 (HOLD) | CGEN | |
| Trailing 12M Revenue (USD) | $76M | $6.4M | Scale | |
| Gross Profit Margin (TTM) | 86.2% | N/A | Quality | |
| PEG Ratio & EV / Revenue | 1.29x PEG · 2.5x EV/Rev | N/M PEG · 85.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $32M EBITDA ($4.3M Net Cash) | -$75M ($1.11 Book/Sh · -55.5% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CGEN +5.41 pp
3M Horizon
CGEN +30.31 pp
6M Horizon
ACRS +1.97 pp
1Y Horizon
ACRS +10.96 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CGEN Revenue | ACRS Revenue | CGEN Op. Margin | ACRS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $20M | $10M | -130.5% | -1378.3% | CGEN |
| FY2019 | N/A | $0M | N/A | -2627.3% | ACRS |
| FY2020 | $0M | $10M | -1574.8% | -785.4% | ACRS |
| FY2021 | $10M | $10M | -584.6% | -1327.1% | CGEN |
| FY2022 | $10M | $30M | -471.7% | -302.0% | ACRS |
| FY2023 | $30M | $30M | -38.8% | -311.6% | CGEN |
| FY2024 | $30M | $20M | -53.4% | -758.2% | CGEN |
| FY2025 | $70M | $10M | 43.1% | -975.9% | CGEN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CGEN
BREAKDOWN
Current IV
89.7%
IV Percentile
57th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ACRS
BREAKDOWN
Current IV
60.7%
IV Percentile
1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CGEN Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
44.9% of Rev ($34M)
90D Engineering Disclosures
0 Published
ACRS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CGEN vs ACRS Key Questions & Quantitative Answers
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas ACRS carries 44.7/100 (HOLD) at $3.38 (N/M Forward P/E, -1412.4% operating margin). Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CGEN leads the Growth & Scale pillar: CGEN posts +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin), compared with ACRS at -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGEN cumulative revenue shifted +250.0% while ACRS shifted +0.0%. In operating R&D and SG&A reinvestment, CGEN deploys 44.9% of Rev ($34M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACRS.
CGEN screens cheaper on headline valuation multiples. CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin), whereas ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 85.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEN (57.2% ROE) versus ACRS (-55.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk). By comparison, ACRS carries 60.7% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.57β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ACRS vs CGEN · Reverse Pair
CGEN vs VCYT
· Sector Peer
ACRS vs ANAB
· Sector Peer
ACRS vs SLDB
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking